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Abstract
Background The increasing use of serial PET/CT scans in
the management of pediatric malignancies raises the
important consideration of radiation exposure in children.
Objective To estimate the cumulative radiation dose from
PET/CT studies to children with malignancy and to
compare with the data in literature.
Materials and methods Two hundred forty-eight clinical
PET/CT studies performed on 78 patients (50 boys/28 girls,
1.3 to 18 years old from December 2002 to October 2007)
were retrospectively reviewed under IRB approval. The
whole-body effective dose (ED) estimates for each child
were obtained by estimating the effective dose from each
PET/CT exam performed using the ImPACT Patient
Dosimetry Calculator for CT and OLINDA for PET.
Results The average number of PET/CT studies was 3.2 per
child(range: 1to14studies).The average EDofanindividual
CT study was 20.3 mSv (range: 2.7 to 54.2), of PET study
was 4.6 mSv (range: 0.4 to 7.7) and of PET/CT study was
24.8 mSv (range: 6.2 to 60.7). The average cumulative
radiation dose per patient from CT studies was 64.4 mSv
(range: 2.7 to 326), from PET studies was 14.5 mSv (range:
2.8 to 73) and from PET/CT studies was 78.9 mSv (range:
6.2 to 399).
Conclusion The radiation exposure from serial PET/CT
studies performed in pediatric malignancies was consider-
able; however, lower doses can be used for both PET and
CT studies. The ALARA principle must be applied without
sacrificing diagnostic information.
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Introduction
The introduction of combined PET/CT has been an
important advancement in the diagnosis, staging, monitor-
S. C. Chawla (*)
Department of Radiology,
Olive View-UCLA Medical Center,
14445 Olive View Drive,
2 D115 Sylmar, CA, USA
e-mail: chawlasoni@gmail.com
N. Federman
Department of Pediatrics,
David Geffen School of Medicine at UCLA,
Los Angeles, CA, USA
D. Zhang
Department of Biomedical Physics,
David Geffen School of Medicine at UCLA,
Los Angeles, CA, USA
K. Nagata
Department of Medicine, Olive View-UCLA Medical Center,
Sylmar, CA, USA
S. Nuthakki
Department of Nuclear Medicine,
David Geffen School of Medicine at UCLA,
Los Angeles, CA, USA
M. McNitt-Gray
Department of Radiology,
David Geffen School of Medicine,
Los Angeles, CA, USA
M. I. Boechat
Department of Radiology,
David Geffen School of Medicine at UCLA,
Los Angeles, CA, USA
Pediatr Radiol (2010) 40:681–686
DOI 10.1007/s00247-009-1434-zing of response to therapy, and surveillance of various
malignancies in adult patients [1, 2]. The role of PET/CT in
the management of children with malignancies is less
clearly defined, although there is a growing body of
literature suggesting that PET/CT is helpful in the overall
management of various pediatric malignancies [3–8].
However, the increasing use of serial PET/CT scans in the
management of pediatric malignancies raises the important
consideration of radiation exposure in children. We esti-
mated the cumulative radiation dose from serial PET/CT
studies in children with malignancies, using our institu-
tion’s standard protocol.
Materials and methods
Institutional review board approval was obtained to perform
a retrospective review of children undergoing clinically
indicated PET/CT studies at our institution. Two hundred
forty-eight clinical PET/CT studies performed on 78
patients (50 boys/28 girls, 3 to 18.5 years of age from
December 2002 to October 2007) were reviewed (Fig. 1).
This review included collecting patient data including age
(at the time of scan), gender, weight, clinical indication,
malignancy and whether the child went on to have radiation
therapy. The review also included first determining the
number and dates of PET/CT as well as CT-only exams that
each child underwent.
For each imaging study, image data was reviewed to
determine the body region that was being examined; the
start and stop location of each series was recorded for later
use in estimating effective dose (ED). This was repeated for
each CTand each PET performed. As part of this review, the
technical parameters for each series were also recorded. For
the CT scan, the following parameters were extracted from
the DICOM headers: (a) scanner make and model (e.g.,
Siemens Emotion Duo), (b) kVp, (c) mA, (d) beam
collimation, (e) rotation time and (f) pitch. For each PET
series, the amount of FDG administered was obtained from
the medical record. At our institution, both the FDG dose
administered and the CT technical parameters were adjusted
for patient weight (for FDG) and patient size (for CT), so
each value had to be recorded individually. It is clinical
practice in our institution to perform the CT scan as a
diagnostic study and not just for attenuation correction; it is
also our practice to use intravenous contrast agent unless
there is a contraindication. In addition, it is our practice to
perform a breath-hold non-contrast CT chest study in
selected patients as needed to evaluate for metastatic disease
in the lungs. It should also be noted that the CTscanner used
in the PET/CT machine (Emotion Duo, Siemens Medical
Solutions, Forcheim, Germany) does not have tube current
modulation capabilities, so the mA value reported was the
fixed mA value used in the study.
Effective dosefromeachCTserieswas estimatedusing the
ImPACTPatientDosimetryCalculator(www.impactscan.org)
(Version 0.99x) with patient-specific scan parameters. This
software package makes use of the National Radiation
Protection Board (NRPB) data sets produced in report
SR250, which provides normalized organ dose data for
irradiation of a mathematical phantom (MIRD phantom) by a
range of CT scanners obtained through Monte Carlo
simulations [9, 10]. The specific parameters obtained from
the DICOM file headers are used as inputs to the software, as
are start and stop locations of the series, which users can
interactively select using a diagram of the MIRD phantom
provided. Based on these inputs, the software estimates the
radiation dose to each organ and then calculates the
estimated whole-body ED in mSv. This was recorded for
each CT series for each patient.
The estimate provided by the ImPACT Dosimetry
Calculator is for a standard adult model, so the ED from
CT was adjusted according to age. This adjustment was
performedbased on resultsreported by Khursheed etal. [11],
who performed a series of Monte Carlo calculations on a
range of phantoms corresponding to newborn, 1-year-old,
5-year-old, 10-year-old, 15-year-old and adult patients [11].
From these results, a table of effective-dose adjustment
factors was created based on an interpolation among the
results obtained for these ages. This is shown in Table 1.
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Fig. 1 Age distribution
Table 1 Factors used to adjust effective dose from CT by patient age;
derived from Khursheed et al [11]
Age in years Factor Age in years Factor
3 1.60 11 1.26
4 1.55 12 1.22
5 1.50 13 1.18
6 1.46 14 1.14
7 1.42 15 1.10
8 1.38 16 1.07
9 1.34 17 1.03
10 1.30 18 1.00
682 Pediatr Radiol (2010) 40:681–686Effective dose from each PET series was estimated using
the OLINDA software (Version 1.0, Vanderbilt University,
Nashville, TN, USA) with patient-specific FDG doses.
OLINDA is a program used to calculate internal radiation
dose estimates for radionuclides used in nuclear medicine.
The program has phantom libraries that permit the calculation
of doses for individuals of different ages and sizes [12].
Nuclide and kinetic models need to be provided by the users.
F-18, whichistheessentialnuclideinFDG,wasspecified.An
absorbed doseestimation study from F-18 FDG by Hayset al.
[13] was used as a kinetic model. Adult male, adult female,
15-year, 10-year, 5-year, 1-year models in OLINDA’s
phantom library were utilized to generate effective dose
conversion factor (mSv/mCi). These factors were then also
interpolated according to different ages, shown in Table 2,
and then multiplied by injected activity (mCi) for each PET
study to get an estimation of effective dose.
Results
The average age of the children in this study was 13.1 years
with a range from 3.0 to 18.5 years. There were 10 children
in the 0- to 5-year-old range, 46 in the 5- to 10-year-old
range, 98 in the 10- to 15-year-old range and 94 in the 15-
to 18-year-old range at the time of the study. The weights of
the children (at time of scan) ranged from 30 to 230
pounds, with an average of 112 pounds.
The typical parameters for the CT study was: 130 kVp
(79.4%) and 110 kVp (20.6%), mA range from 43 to 170
with an average of 111.3, rotation time of either 0.8 s or
1.0 s, pitch range from 1.0 to 1.3 and the vast majority had
a beam collimation of 2×5 mm. The majority of these scans
were from the mid-brain to mid-thigh. For the PET portion,
0.21 mCi/kg of FDG was given on a straight weight basis.
The average number of PET/CTstudies was 3.2 per patient
(range: 1–14) (Fig. 2). The average effective dose of an
individual CTstudy was 20.3 mSv (range: 2.7–54.2) (Fig. 3),
of PET study was 4.6 mSv (range: 0.4–7.7) (Fig. 4)a n do f
PET/CT study was 24.8 mSv (range: 6.2–60.7) (Fig. 5).
The average cumulative dose per patient from CTstudies
was 64.4 mSv (range: 2.7–326) (Fig. 6), from PET studies
was 14.5 mSv (range: 2.8–73) (Fig. 7) and from PET/CT
studies was 78.9 mSv (range: 6.2–399) (Fig. 8).
Radiation doses varied significantly depending on the
number of studies as well as the number of additional CT
scans performed. A total of 199 chest CT scans were
performed to evaluate the metastatic disease in the lungs.
The average effective dose of an individual chest CT study
was 2.8 mSv (range: 0.43–7.9). Fifty-eight percent (45
children) received no radiation therapy and 42% (33
patients) received radiation therapy. Twenty-seven percent
(21 children) of all patients received >100 mSv cumulative
dose; this consisted of 9% (7 children) with no radiation
therapy, and 18% (14 children) with radiation therapy.
Figures 9 and 10 show the effective dose distribution from
an individual PET/CT and cumulative PET/CT as function
of age groups (0–5 years, 5–10 years and >10 years).
Discussion
The radiation exposure from PET/CT studies is consider-
able, especially for those children undergoing regular
Table 2 Effective dose conversion factors from PET for both male
and female pediatric patients as a function of age
Age in years Effective dose
(mSv/mCi)
Age in years Effective dose
(mSv/mCi)
Male Female Male Female
3 1.12 1.12 11 0.49 0.50
4 0.95 0.95 12 0.45 0.48
5 0.78 0.78 13 0.42 0.46
6 0.73 0.73 14 0.39 0.44
7 0.68 0.68 15 0.35 0.42
8 0.62 0.62 16 0.33 0.40
9 0.57 0.57 17 0.30 0.38
10 0.52 0.52 18 0.27 0.36
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Fig. 3 Effective dose (mSv) of an individual CT study
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Pediatr Radiol (2010) 40:681–686 683follow-up exams. Radiation doses vary significantly
depending on the number of PET/CT studies performed.
The results from this study demonstrate that the largest
portion of the radiation dose comes from the CT portion of
the examination. The effective doses from the CT studies
ranged from 2.7 to 54.2 mSv and nearly half of the studies
exceeded 20 mSv. These studies all involved “full-body”
CT scans, which ranged from mid-brain to mid-thigh and
thus irradiated essentially all of the radiosensitive organs.
The techniques for these scans were usually adjusted for
patient size with kVp and/or mAs being reduced for
smaller/younger patients. For those studies exceeding
20 mSv, a typical set of technical parameters was
130 kVp, 100 to 130 mA, 1-s rotation time, 2×5-mm beam
collimation and pitch 1. After performing the age adjust-
ment described above, this would often result in effective
doses that exceeded 20 mSv. This effective dose is actually
reasonably consistent with the effective doses received by
adults undergoing similar anatomic coverage, even though
the technical factors (e.g., mA) would be increased due to
the increased size of the adult patient. It should also be
noted that the average age of our patient population was
13.1 years at the time of the study, that 77% of our patient
population was >10 years old and that average weights
were 112 pounds with 64% exceeding 100 pounds.
The long-term effects of the treatment of pediatric
malignancies are numerous and substantial. These include
development of cardiomyopathy, avascular necrosis of the
hip, cognitive delay, early onset of heart disease, pulmonary
fibrosis and increased risk of secondary malignancies.
Children who receive alkylating chemotherapeutic agents
and radiation as part of their treatment regimens are at
particular risk for developing secondary malignancies. The
increasing use of PET/CT in the management of pediatric
malignancies raises the important issue of radiation expo-
sure in children, particularly when it is reported that
children have an increased risk of developing secondary
malignancies from radiation exposure compared with
adults. In fact, by extrapolating data from atomic bomb
survivors, this increased risk is by an order of magnitude
greater than that of adults [14–16]. It has been estimated,
but not proved, that the lifetime cancer risk of a 1-year-old
who has received an abdominal CT is 1 in 550 [17]. At
doses of 100 mSv or greater (21% of the patients reported),
the cancer risk has been estimated at 1 in 100 individuals
[18]. Judicious use of imaging is fundamental for the
management of these patients, using tailored protocols that
follow the ALARA principle (as low as reasonably
achievable) to obtain diagnostic information.
The significance of incremental radiation exposure from
serial PET/CT scans for children who have received high-
dose radiation therapy as part of their treatment is not
known. The significance of the incremental exposure may
also depend on the location of radiation; for example, one
could compare patients who receive mantle radiation versus
limited radiation to a distal extremity. We suggest that the
cumulative radiation dose to organs such as the lung, heart,
thyroid, gonads, etc., is significant.
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684 Pediatr Radiol (2010) 40:681–686We have estimated the dose of radiation from serial PET/
CT scans in pediatric patients, but it is important to note
that the cumulative radiation from other imaging modalities
has not been included. These imaging modalities include
the technetium 99 bone scans,
123Iodine MIBG (metaiodo-
benzylguanidine) scans, interval CT studies for acute events
and fluoroscopy, which also add to the radiation dose.
It is necessary to apply the ALARA principle in the
radiation exposure of PET/CT without sacrificing diagnos-
tic information. The greatest contributor to overall radiation
exposure in PET/CT is the whole-body diagnostic CT. It is
widely accepted that by decreasing the tube current (mA)
value on the CT portion the radiation dose can be reduced
substantially. It is clear that until the standards of frequency,
interval and number of needed PET/CT scans is established
in the management of pediatric malignancies, that the use
of PET/CT in children should be used judiciously on a
case-by-case basis with particular emphasis on the risk,
benefit and cumulative radiation dose to children. We have
reviewed the CT protocols for all pediatric studies at our
institution and decreased doses following “image gently”
guidelines, according to patient weight. Doses of FDG for
PET have also been reduced to 0.14 mCi/Kg, as recom-
mended in the literature. We are now monitoring all
pediatric CTs and PET/CT studies for dose (Table 3).
Alternative approaches to the use of whole-body PET/
CT include routine CT or PET/CT limited to the area of
interest, intercalated by periodic whole-body PET/CT, and
whole-body PET followed by limited CT in areas of PET-
positive lesions (albeit with some reduced sensitivity).
Whole-body PET/CT continues to be an important
noninvasive diagnostic/staging modality for certain malig-
nancies such as Hodgkin and non-Hodgkin lymphomas,
and it is thought that alternative or more cautious
approaches should be weighed against the unequivocal
benefit provided. In order to reduce the radiation exposure
from imaging studies in children with cancer we suggest the
following guidelines:
1. Strict adherence to the ALARA principle. This may
involve decreasing the CT tube (mA) current and
avoidance of whole-body scans when only a limited
scan is sufficient.
2. Use of pediatric protocols and, when possible, imaging
at pediatric centers where radiologists and technicians
are acutely aware of the need to reduce radiation
exposure.
3. Establishment of formal guidelines for the interval,
number, and frequency of PET/CT scans for each
pediatric malignancy.
4. When appropriate, use of modalities such as MR or US
to reduce radiation exposure.
5. Overall attention to the cumulative radiation exposure
for each child.
Cumulative PET-CT dose (mSv) as function
of age
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Fig. 10 Cumulative PET-CT dose (mSv) as function of age
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Fig. 9 Individual PET-CT dose (mSv) as function of age
Table 3 Current parameters for CT chest and abdomen at our
institution
KV mAs KV mAs
<5 kg 80 45 80 45
6–15 kg 80 55 80 55
16–60 kg 100 55 100 65
>61 kg 120 55 120 65
Cumulative dose (mSv) per patient from
Cumulative dose per patient (mSv)
PET/CT studies (Average 78.9, Range: 6.2 - 399)
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Pediatr Radiol (2010) 40:681–686 685Conclusion
The radiation exposure from serial PET/CTstudies performed
in pediatric malignancies can be considerable. The ALARA
principle must be applied without sacrificing diagnostic
information either by reducing CT tube current or by
considering alternative diagnostic approaches such as limited
CTscan length or non-radiating modalities like MR and US.
PET/CT continues to be an important noninvasive
diagnostic, staging, and surveillance modality for certain
pediatric malignancies. The decision to utilize PET/CT in
children should be made on an individual basis with
particular awareness to the cumulative radiation exposure
and the overall benefit of the scan.
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